Neuroimaging with PET/CT in chronic traumatic encephalopathy: what nuclear medicine can do to move the field forward.
Expert Rev Mol Diagn
; 22(2): 149-156, 2022 Feb.
Article
en En
| MEDLINE
| ID: mdl-35086415
ABSTRACT
INTRODUCTION:
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative syndrome, caused by single or repeated traumatic brain injuries. Since a few years ago, post mortem examination represented the only effective method to diagnose CTE through the detection of its peculiar neuropathological features (i.e. tau protein aggregates) at a macroscopic and microscopic level. Several efforts have been made to develop radiopharmaceuticals characterized by high affinity for tau aggregates, suitable for imaging through positron emission computed tomography (Tau-PET). AREAS COVERED The various radiopharmaceuticals utilized for the molecular imaging of CTE through Tau-PET are covered, with specific reference to their applications in clinical practice. Furthermore, PET probes binding to the translocator protein (TSPO), a marker of brain injury and repair, are reviewed as potential tools for the imaging of neuroinflammatory cascade associated with CTE. EXPERT OPINION Molecular neuroimaging of CTE with Tau-PET is an intriguing, although still not completely explored, tool for the in vivo detection and monitoring of neuropathological hallmarks associated with CTE. Furthermore, some novel tracers, such as TSPO-ligands, hold the promise to get an insight into the complex physiopathological mechanisms leading from brain injury to symptomatic CTE.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Encefalopatía Traumática Crónica
/
Medicina Nuclear
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
Expert Rev Mol Diagn
Asunto de la revista:
BIOLOGIA MOLECULAR
Año:
2022
Tipo del documento:
Article